PPARδ in humans: Genetic and pharmacological evidence for a significant metabolic function

Current Opinion in Lipidology

Volumn 20, Issue 4, 2009, Pages 333-336

  Karpe, Fredrik ^a,b   Ehrenborg, Ewa E ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Free fatty acids; Hyperlipoproteinaemia; LDL; VLDL

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ATORVASTATIN; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; UNCLASSIFIED DRUG; FATTY ACID; LOW DENSITY LIPOPROTEIN; THIAZOLE DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; DRUG POTENCY; DYSLIPIDEMIA; FATTY ACID OXIDATION; GENE; GENETIC ASSOCIATION; HUMAN; HYPERLIPIDEMIA; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PHENOTYPE; PPARD GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; GENETIC VARIABILITY; GENETICS; HYPERLIPOPROTEINEMIA; LIPID METABOLISM; METABOLISM;

RODENTIA;

ANIMALS; FATTY ACIDS; GENETIC VARIATION; HUMANS; HYPERLIPOPROTEINEMIAS; LIPID METABOLISM; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; PHENOTYPE; PPAR DELTA; THIAZOLES;

EID: 68449095060     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832dd4b1     Document Type: Review

References (23)

1. Muoio DM, MacLean PS, Lang DB, et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002; 277:26089-26097.
2. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116:590-597.
3. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134:405-415.
4. Zhang J, Fu M, Zhu X, et al. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes postconfluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002; 277:11505-11512.
5. Piqueras L, Reynolds AR, Hodivala-Dilke KM, et al. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:63-69.
6. Skogsberg J, Kannisto K, Cassel TN, et al. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003; 23:637-643.
7. Skogsberg J, McMahon AD, Karpe F, et al. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 2003; 254:597-604.
8. Aberle J, Hopfer I, Beil FU, Seedorf U. Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 2006; 3:108-111.
9. Chen S, Tsybouleva N, Ballantyne CM, et al. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 2004; 14:61-71.
10. Gouni-Berthold I, Giannakidou E, Faust M, et al. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in nondiabetic controls. Atherosclerosis 2005; 183:336-341.
11. Shin HD, Park BL, Kim LH, et al. Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 2004; 53:847-851.
12. Hu C, Jia W, Fang Q, et al. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet Med 2006; 23:1307-1312.
13. Saez ME, Grilo A, Moron FJ, et al. Interaction between calpain 5, peroxisome proliferator-activated receptor-gamma and peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity. Cardiovasc Diabetol 2008; 7:23.
14. Grarup N, Albrechtsen A, Ek J, et al. Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 2007; 50:1201-1208.
15. Vanttinen M, Nuutila P, Kuulasmaa T, et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. Diabetes 2005; 54:3587-3591.
16. Hautala AJ, Leon AS, Skinner JS, et al. Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study. Am J Physiol Heart Circ Physiol 2007; 292:H2498-H2505.
17. Thamer C, Machann J, Stefan N, et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab 2008; 93:1497-1500.
18. Stefan N, Thamer C, Staiger H, et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007; 92:1827-1833.
19. Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta-87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 2007; 31:411-417.
20. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007; 27:359-365.
21. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008; 57:332-339.
22. Brand MD, Affourtit C, Esteves TC, et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 2004; 37:755-767.
23. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in noninsulin-dependent diabetes mellitus. J Clin Invest 1994; 94:2349-2356.